Intravitreal Ranibizumab for Macular Edema Secondary to Juxtafoveal Retinal Telangiectasia Type 1A
|Ruwan A. Silva1 and Ninel Z. Gregori1,2*|
|1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA|
|2Clinical Ophthalmology Bascom Palmer Eye Institute, University of Miami Miller School of Medicine Chief of Ophthalmology Section, Miami VA Medical Center, Miami, USA|
|Corresponding Author :||Ninel Gregori, MD
Assistant Professor of Clinical Ophthalmology Bascom Palmer Eye Institute
University of Miami Miller School of Medicine Chief of Ophthalmology Section
Miami VA Medical Center, Miami, USA
Tel: 305-326-6000, 305-575-7000; Ext: 4592
E-mail: [email protected]
|Received November 07, 2011; Accepted December 06, 2011; Published December 10, 2011|
|Citation: Silva RA, Gregori NZ (2011) Intravitreal Ranibizumab for Macular Edema Secondary to Juxtafoveal Retinal Telangiectasia Type 1A. J Clinic Experiment Ophthalmol 2:195. doi:10.4172/2155-9570.1000195|
|Copyright: © 2011 Silva RA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Purpose: To describe the clinical, angiographic, and optical coherence tomography (OCT) findings of a patient with cystoid macular edema (CME) in juxtafoveal retinal telangiectasis (JXT) treated with intravitreal ranibizumab injections.
Methods: In the setting of a tertiary referral center, a patient with a long history of Leber’s miliary aneurysms was later diagnosed with ipsilateral juxtafoveal retinal telangiectasis (JXT) type 1A with associated CME. The patient was treated with eight intravitreal injections of 0.5 mg of ranibizumab and followed with examination and Spectral-Domain Optical Coherence Tomography (OCT) for 14 months.
Results: At baseline, fluorescein angiography demonstrated macular telangiecatasis and aneurysms with late leakage. The OCT showed a large area of intraretinal fluid in the area of telangiectasis. CME resolved after the first intravitreal ranibizumab injection and the vision gradually improved from 20/50 to 20/20−1 over 5 months. Repeat ranibizumab injections were required to keep the macula dry over 14 months. No adverse events were noted.
Conclusions: Intravitreal ranibizumab injections resulted in restoration of macular architecture and vision improvement in a patient with JXT type 1A. Ranibizumab should be considered as a treatment option in this condition.